21st Century Therapeutics is a product-focused, development-oriented biotech company that very soon after being founded placed six anti-tumor compounds into human clinical studies through licensing to pharmaceutical companies. The firm's exclusive ORION discovery and development platform combines a unique and novel in vitro Solid Tumor Selective (STS) technology with an exclusive Chemistry, Clonogenic, Formulation and Pharmacology studies (CCFP) platform to ensure that its drugs will be bioavailable and active in subsequent in vivo Therapeutic Assessment. Data from all these components, together with a Molecular Brushing (MB) platform, are blended in a proprietary manner to identify and characterize potential clinical strengths and weaknesses of an experimental anti-cancer drug. The added value of this approach includes early stage prediction of the drugâs therapeutic effectiveness in humans as well as the novel target mechanism by which it acts
